ACI Hatch-Waxman and BPCIA Virtual Proficiency Series
October 5, 2021

On October 5, Axinn partner Chad Landmon participated in a panel entitled, "Identifying and Comprehending Pre-Commercialization Concerns Relative to Small Molecules and Biologics" at ACI’s Hatch-Waxman and BPCIA Virtual Proficiency Series.

This session examined the current pre-commercialization landscape and considerations in light of Health Care Reform.

Click here for more information.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.